The abstract is read at the publisher; the summary is JClub's.
AZ191 downregulates MMGT1 in triple-negative breast cancer, suppressing tumor growth and enhancing anti-PD-1 immunotherapy efficacy in vivo.
- Why it matters: Senescent tumor cells can shape the immune microenvironment, but how MMGT1-driven senescence control affects immunotherapy response in TNBC is unclear.
- What they did: The study assessed MMGT1 in TNBC, including mammary gland-specific Mmgt1 knockout and mechanistic testing of SCAP-SREBP1 Golgi translocation, plus CCL20-driven effects on CD8+ T cells.
- The result: MMGT1 upregulation in TNBC correlates with poor prognosis, and its inhibition via AZ191 suppresses tumors while improving anti-PD-1 outcomes, supporting MMGT1 as an immunotherapy target.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.